Spero Therapeutics
NASDAQ:
SPRO-USD
$1.44
0.00%
Spero Therapeutics is a biotechnology business based in the US. Spero Therapeutics shares (SPRO.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $1.44 – an increase of 2.14% over the previous day. Spero Therapeutics employs 46 staff and has a trailing 12-month revenue of around $103.8 million.
How to buy shares in Spero Therapeutics
- Choose a platform. If you're a beginner, our stock trading platform picks below can help you choose.
- Open your account. Provide your personal information and sign up.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: SPRO in this case.
- Research stocks. The platform should provide the latest information available.
- Buy your stocks. Place a market order or limit order with your preferred number of shares. It's that simple.
Our top picks for buying Spero Therapeutics stock
Commission-free stock trading
- No-cost financial planning and automated investing
- $0 commission on stocks, ETFs and options
- Get up to $1,000 in stock when you fund a new account within 30 days
$200 in US stocks
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Get $100-$5,000 when you open an account with $5,000 to $1,000,000+
Easy access to diverse assets
- Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
- Earn 5.1% APY on your cash
- Earn a $0.18 rebate on options, with no commissions and no per-contract fees
Is it a good time to buy Spero Therapeutics stock?
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Use our graph to track the performance of SPRO stocks over time.
Share price volatility
Over the last 12 months, Spero Therapeutics's shares have ranged in value from as little as $0.99 up to $1.995. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spero Therapeutics's is 0.575. This would suggest that Spero Therapeutics's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $1.435
| 1 week (2024-04-16) | -4.33% |
|---|---|
| 1 month (2024-03-21) | -18.00% |
| 3 months (2024-01-23) | -8.60% |
| 6 months (2023-10-23) | 35.38% |
| 1 year (2023-04-23) | -16.08% |
| 2 years (2022-04-18) | -75.88% |
| 3 years (2021-04-22) | -89.11% |
| 5 years (2019-04-23) | -88.38% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Buy Spero Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 6 of 6
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is Spero Therapeutics under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Spero Therapeutics P/E ratio, PEG ratio and EBITDA
Spero Therapeutics's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Spero Therapeutics stocks trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Spero Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.2 million.
The EBITDA is a measure of a Spero Therapeutics's overall financial performance and is widely used to measure a its profitability.
Frequently asked questions
More guides on Finder
-
NinjaTrader review 2024
A deep dive into the highlights and limitations of NinjaTrader.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
10 best brokerage account bonuses of 2024
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
Methodology for robo-advisors
We rate robo-advisors across eight key categories, including ongoing costs, minimum deposit requirements, portfolio mix and more.
-
Public.com review 2024
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
SoFi Invest® review 2024
SoFi is a commission-free platform with both active and automated investment accounts.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy gold
Learn how to buy physical gold and compare gold bullion dealers.
-
Charles Schwab review 2024
Take advantage of $0 trades and no investment minimums with this well-known broker.
Ask a Question